JP2022543136A5 - - Google Patents
Info
- Publication number
- JP2022543136A5 JP2022543136A5 JP2022506919A JP2022506919A JP2022543136A5 JP 2022543136 A5 JP2022543136 A5 JP 2022543136A5 JP 2022506919 A JP2022506919 A JP 2022506919A JP 2022506919 A JP2022506919 A JP 2022506919A JP 2022543136 A5 JP2022543136 A5 JP 2022543136A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- approximately
- dose
- apoc3
- composition according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2025012194A JP2025061882A (ja) | 2019-08-05 | 2025-01-28 | Ａｐｏｃ３関連疾患および障害の処置のための方法 |
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962883046P | 2019-08-05 | 2019-08-05 | |
| US62/883,046 | 2019-08-05 | ||
| US201962936559P | 2019-11-17 | 2019-11-17 | |
| US62/936,559 | 2019-11-17 | ||
| US202062970613P | 2020-02-05 | 2020-02-05 | |
| US62/970,613 | 2020-02-05 | ||
| PCT/US2020/044879 WO2021026150A1 (en) | 2019-08-05 | 2020-08-04 | Methods for the treatment of apoc3-related diseases and disorders |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025012194A Division JP2025061882A (ja) | 2019-08-05 | 2025-01-28 | Ａｐｏｃ３関連疾患および障害の処置のための方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2022543136A JP2022543136A (ja) | 2022-10-07 |
| JP2022543136A5 true JP2022543136A5 (OSRAM) | 2023-08-14 |
| JP7829478B2 JP7829478B2 (ja) | 2026-03-13 |
Family
ID=74503223
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022506919A Active JP7829478B2 (ja) | 2019-08-05 | 2020-08-04 | Ａｐｏｃ３関連疾患および障害の処置のための方法 |
| JP2025012194A Pending JP2025061882A (ja) | 2019-08-05 | 2025-01-28 | Ａｐｏｃ３関連疾患および障害の処置のための方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025012194A Pending JP2025061882A (ja) | 2019-08-05 | 2025-01-28 | Ａｐｏｃ３関連疾患および障害の処置のための方法 |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20220152079A1 (OSRAM) |
| EP (1) | EP4010075A4 (OSRAM) |
| JP (2) | JP7829478B2 (OSRAM) |
| KR (1) | KR20220044551A (OSRAM) |
| CN (1) | CN114555188A (OSRAM) |
| AU (1) | AU2020324974B2 (OSRAM) |
| CA (1) | CA3147725A1 (OSRAM) |
| MX (1) | MX2022001460A (OSRAM) |
| TW (1) | TW202120104A (OSRAM) |
| WO (1) | WO2021026150A1 (OSRAM) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP6989521B2 (ja) * | 2016-09-02 | 2022-01-05 | アローヘッド ファーマシューティカルズ インコーポレイテッド | 標的化リガンド |
| CN114934074A (zh) * | 2022-06-01 | 2022-08-23 | 北京大学 | 一种ApoC3基因敲除仓鼠模型的构建方法 |
| EP4706646A1 (en) | 2023-06-01 | 2026-03-11 | Sunshine Lake Pharma Co., Ltd. | Novel double-stranded sirna, conjugate thereof, and use thereof |
| KR20260032888A (ko) * | 2024-08-30 | 2026-03-10 | 올릭스 주식회사 | APOC3 유전자를 표적으로 하는 RNAi 제제 및 이의 용도 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2768091T3 (es) * | 2009-02-10 | 2020-06-19 | Amarin Pharmaceuticals Ie Ltd | Uso del éster etílico del ácido eicosapentaenoico para tratar la hipertrigliceridemia |
| EP3444348A1 (en) | 2011-06-21 | 2019-02-20 | Alnylam Pharmaceuticals, Inc. | Angiopoietin-like 3 (angptl3) irna compositions and methods of use thereof |
| KR20230084331A (ko) * | 2011-06-21 | 2023-06-12 | 알닐람 파마슈티칼스 인코포레이티드 | 아포리포단백질 c-iii(apoc3) 유전자의 발현 억제를 위한 조성물 및 방법 |
| CA2968114A1 (en) * | 2014-11-17 | 2016-05-26 | Alnylam Pharmaceuticals, Inc. | Apolipoprotein c3 (apoc3) irna compositions and methods of use thereof |
| AU2017376950B2 (en) * | 2016-12-16 | 2024-02-22 | Alnylam Pharmaceuticals, Inc. | Methods for treating or preventing TTR-associated diseases using transthyretin (TTR) iRNA compositions |
| EP3630788A4 (en) | 2017-06-02 | 2021-04-28 | Wave Life Sciences Ltd. | OLIGONUCLEOTIDE COMPOSITIONS AND METHODS FOR THEIR USE |
| TN2020000039A1 (en) * | 2017-09-11 | 2021-10-04 | Arrowhead Pharmaceuticals Inc | Rnai agents and compositions for inhibiting expression of apolipoprotein c-iii (apoc3) |
| US11660347B2 (en) * | 2017-12-01 | 2023-05-30 | Suzhou Ribo Life Science Co., Ltd. | Nucleic acid, composition and conjugate containing same, preparation method, and use thereof |
-
2020
- 2020-08-04 JP JP2022506919A patent/JP7829478B2/ja active Active
- 2020-08-04 MX MX2022001460A patent/MX2022001460A/es unknown
- 2020-08-04 CA CA3147725A patent/CA3147725A1/en active Pending
- 2020-08-04 AU AU2020324974A patent/AU2020324974B2/en active Active
- 2020-08-04 CN CN202080069368.7A patent/CN114555188A/zh active Pending
- 2020-08-04 EP EP20851025.5A patent/EP4010075A4/en active Pending
- 2020-08-04 WO PCT/US2020/044879 patent/WO2021026150A1/en not_active Ceased
- 2020-08-04 KR KR1020227007372A patent/KR20220044551A/ko active Pending
- 2020-08-05 TW TW109126581A patent/TW202120104A/zh unknown
-
2022
- 2022-02-03 US US17/592,182 patent/US20220152079A1/en active Pending
-
2025
- 2025-01-28 JP JP2025012194A patent/JP2025061882A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2015520188A5 (OSRAM) | ||
| TW201100093A (en) | Preparation comprising insulin, nicotinamide and an amino acid | |
| JP7818412B2 (ja) | デュラグルチドを使用する方法およびデュラグルチドを含有する組成物 | |
| JP2025096283A5 (OSRAM) | ||
| CN103038356A (zh) | 乙酰半胱氨酸组合物及其使用方法 | |
| JP2022173519A (ja) | 神経筋疾患、神経変性疾患、自己免疫疾患、発達疾患および／または代謝疾患の処置のための、脳由来神経栄養因子（ｂｄｎｆ）の誘導された発現 | |
| JP2023061957A (ja) | 抑うつ障害の処置 | |
| JP6440843B2 (ja) | 脂肪代謝の調節に供する医薬品の製造のための第一鉄アミノ酸キレートを含む組成物の使用 | |
| JP2018531605A5 (OSRAM) | ||
| JP2022518944A5 (OSRAM) | ||
| JP7829478B2 (ja) | Ａｐｏｃ３関連疾患および障害の処置のための方法 | |
| JP5837877B2 (ja) | 静脈内投与イブプロフェンを用いた患者の治療 | |
| WO2024042518A1 (en) | Glp-1 receptor antagonist and methods of use thereof | |
| KR20120138229A (ko) | 정맥내 투여용 이부프로펜을 이용한 중증 환자의 치료 | |
| TW202417015A (zh) | 以非妥西蘭治療血友病 | |
| US20240358668A1 (en) | Methods and compisitions for ameliorating biomarkers associated with cardiovascualr risk using (r)-2-amino-3-phenylpropyl carbamate | |
| KR20210087952A (ko) | 운동 장애들을 치료하기 위한 가복사돌, 가낙솔론 및 알로프레그나놀론의 사용 | |
| JP2025500412A (ja) | 血友病患者において患者報告アウトカムを改善するのに使用するためのフィツシラン | |
| US20230348586A1 (en) | Therapeutic agents and uses thereof | |
| JP2013500964A (ja) | 静脈内イブプロフェンを用いた重篤な病気の患者の治療 | |
| TW202220650A (zh) | 5-甲基-1,2,4-噁二唑-3-基化合物之低劑量療法及調配物 | |
| EP3996679A1 (en) | High concentration insulin formulation | |
| JP2003171266A (ja) | キシリトールを含有する解熱性調剤 | |
| Nuffer et al. | The Role of inhaled insulin in the management of Type 2 Diabetes | |
| JP2012025734A (ja) | 骨髄異形性症候群を治療するための組成物および方法 |